DURHAM, N.C.--(BUSINESS WIRE)--FHI Clinical Inc. announces today it has partnered with Infectious Disease Research Institute (IDRI), a Seattle-based not-for-profit organization, to provide full-service contract research organization (CRO) capabilities for an immunotherapy clinical trial to combat moderate to severe cases of COVID-19.
IDRI recently announced it has received funding from New Jersey-based Celularity, a clinical-stage cell therapeutics company, to launch a clinical trial to investigate the use of Celularity’s NK cell therapy, currently under study for the treatment of various hematologic cancers and solid tumors, as a potential treatment option against the novel coronavirus.
In a recent interview, Dr. Corey Casper, CEO of IDRI, explained that the targeted therapy will “essentially be a way of giving patients the immune cells that are critical in fighting this infection.” Casper is hopeful this immunotherapy can be introduced to the market within a year, pending clinical trial success.
“When an outbreak like coronavirus occurs, new therapies and vaccines are vital and require rapid start-up of clinical trials,” commented Ted FitzGerald, FHI Clinical president and CEO. “Our extensive experience in past outbreaks and global epidemics positions us to lead a diligent, coordinated response while providing high-quality services in this rapidly evolving public health crisis.”
For more information on the importance of building research capacity in an outbreak setting, leveraging existing research capacity, and strengthening and localizing health systems, please refer to the FHI Clinical Outbreak Response Guide.
About FHI Clinical
FHI Clinical is a full-service contract research organization (CRO) with the global expertise, responsive approaches and proven solutions to manage complex clinical research in resource-limited settings around the world. Our mission is to address unmet research needs and achieve maximum social impact by supporting the development of life-saving vaccines and medicines. Visit fhiclinical.com or contact us at firstname.lastname@example.org or 919.321.3321 to learn how we can put our diverse clinical and operational expertise to work for you.
IDRI is a Seattle-based not-for-profit organization committed to applying innovative science to the research and development of products to prevent, detect and treat infectious diseases of global importance. By integrating capabilities, we strive to enable an efficient pathway to bring scientific innovation from the lab to the people who need it most. For more information, please refer to idri.org.